Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress
24 févr. 2022 07h30 HE
|
Intellia Therapeutics, Inc.
On track to present additional interim data from dose-escalation portion of the ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy on February 28, at 4:30 p.m....
Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies
23 févr. 2022 08h00 HE
|
Intellia Therapeutics, Inc.
State-of-the-art GMP manufacturing facility to support preclinical through commercial production of Intellia’s investigational therapiesNew facility in Waltham, Massachusetts expected to be...
Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022
17 févr. 2022 07h30 HE
|
Intellia Therapeutics, Inc.
Fourth quarter and full-year 2021 financial results – February 24, at 8:00 a.m. ETUpdated interim clinical data from the ongoing Phase 1 study of NTLA-2001 for the treatment of transthyretin (ATTR)...
Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer
15 févr. 2022 07h30 HE
|
Intellia Therapeutics, Inc.
Collaboration combines Intellia’s genome editing platform with ONK’s optimized natural killer (NK) cell therapy platform Intellia grants ONK non-exclusive rights to its ex vivo genome editing and LNP...
Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics
03 févr. 2022 07h30 HE
|
Intellia Therapeutics, Inc.
Rewrite Therapeutics’ proprietary and versatile DNA writing platform enables a range of novel genome editing strategiesAcquisition further expands Intellia’s industry-leading genome editing toolbox by...
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022
06 janv. 2022 07h30 HE
|
Intellia Therapeutics, Inc.
Advance clinical development of NTLA-2001, a potential single-dose therapy for transthyretin (ATTR) amyloidosis; on track to present additional data from Phase 1 study in Q1 2022Achieve preliminary...
Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
05 janv. 2022 16h01 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging...
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases
05 janv. 2022 07h30 HE
|
Intellia Therapeutics, Inc.
— Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation CD19 CAR T-cell therapy to treat autoimmune...
Intellia Therapeutics Appoints Derek Hicks as Chief Business Officer
20 déc. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9...
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
13 déc. 2021 07h30 HE
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...